- Reviews & Citations

CD200,MOX1,MOX2,MRC,OX-2,My033
Biotinylated Human CD200, Fc (L234A, L235A, P329G),Avitag (OX2-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Gly 232 (Accession # P41217-1).
Predicted N-terminus: Gln 31
Request for sequence
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 50.6 kDa. The protein migrates as 70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Passed as determined by the HABA assay / binding ELISA.
Less than 0.1 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
CD200 is also known as OX-2 membrane glycoprotein (OX-2), is a type-1 membrane glycoprotein, which contains two immunoglobulin domains (1 Ig-like C2-type (immunoglobulin-like) domain and Ig-like V-type (immunoglobulin-like) domain), and thus belongs to the immunoglobulin superfamily. CD200 / OX-2 is widely expressed in multiple cell types. CD200 interacts with a structurally related receptor (CD200R) expressed mainly on myeloid cells and is involved in regulation of macrophage and mast cell function. OX-2 / CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.